Mellitus Company
Mellitus is developing a novel in vitro diagnostic test for the measurement of Glycated CD59 (GCD59) with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a clinical trial test for pharmaceutical development. Its technology is based on the measurement of a novel biomarker called Glycated CD59 (GCD59). It was founded in 2011 and is headquartered in Boston, Massachusetts.
Industry:
Biomarkers for Longevity
Headquarters:
Boston, Massachusetts, United States
Zip:
1-10
Founded Date:
2011-01-01
Employees Number:
1-10
Acquisitions Number:
1
Investors Number:
13762866
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Undisclosed
Last Funding Type:
Undisclosed
Register and Claim Ownership